Status:
UNKNOWN
Prostate Artery Embolization: Single Center Experience
Lead Sponsor:
University of Mississippi Medical Center
Conditions:
Benign Prostatic Hyperplasia (BPH)
Lower Urinary Tract Symptoms
Eligibility:
MALE
45+ years
Phase:
NA
Brief Summary
Benign prostatic hyperplasia (BPH) is an enlarged prostate gland from smooth muscle and glandular hyperplasia seen in the aging population with a prevalence of upto 90% in patients in the ninth decade...
Detailed Description
Benign prostatic hyperplasia (BPH) is an enlarged prostate from smooth muscle and glandular hyperplasia that results in lower urinary tract symptoms due to bladder outlet obstruction. It is seen in 8%...
Eligibility Criteria
Inclusion
- Anyone with international prostate symptom score greater than or equal to 8 (moderate to severe lower urinary tract symptoms)
- Quality of life assessment greater than 3
- Prostate volume greater than 40 cm3
- Men \>45 years old
- Indwelling urinary catheter secondary to benign prostatic hyperplasia or moderate-severe lower urinary tract symptoms
Exclusion
- Evidence of tortuous or severe atherosclerotic vessels on CT
- Neurogenic bladder
- \<8 international prostate symptoms score
- Prostate volume less than 40cm3
- History of prostate cancer
Key Trial Info
Start Date :
March 17 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 10 2023
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT04766268
Start Date
March 17 2021
End Date
April 10 2023
Last Update
February 24 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Mississippi Medical center
Jackson, Mississippi, United States, 39211